Firefly BioWorks

About:

Firefly BioWorks offers an open platform for industrial, academic, and clinical scientists to develop and use multiplexed biological assays.

Website: http://fireflybio.com

Twitter/X: fireflybio

Top Investors: Sands Capital Ventures, Massachusetts Life Sciences Center

Description:

Firefly BioWorks, Inc. (Cambridge, MA) is introducing an open platform allowing industrial, academic and clinical scientists to develop and use multiplexed biological assays on standard laboratory instrumentation. The company's core technology, Optical Liquid Stamping, was developed in the Chemical Engineering Department at MIT (News - Alert) by Firefly co-founders. The method allows rapid and scalable synthesis of encoded, multi-functional particles for the quantification of biological function. The company's long-term vision is to provide research and clinical scientists with reliable and affordable solutions for the comprehensive monitoring of biological systems.

Total Funding Amount:

$3.4M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2010-01-01

Contact Email:

info(AT)fireflybio.com

Founders:

Daniel C. Pregibon, Davide M. Marini, Patrick S. Doyle

Number of Employees:

11-50

Last Funding Date:

2014-07-21

IPO Status:

Private

Industries:

© 2025 bioDAO.ai